Medacta Group (MOVE) H2 2024 TU earnings summary

Executive summary

• FY 2024 revenue reached €590.6 million, up 16.2% in constant currency and 15.6% in Euro, with strong growth across all geographies and business lines, driven by innovation and surgeon education.

• Four-year CAGR from 2020 to 2024 stands at 18.1%, reflecting sustained momentum across all product lines and geographies.

• Expansion of the team with 177–180 new employees supported operational excellence, growth, and surgeon engagement.

Financial highlights

• Revenue for 2024 was €590.6 million, up 16.2% year-over-year in constant currency.

• EMEA and North America both grew 16.5%, Asia-Pacific 14.5%, and Latin America 22.5%.

• Product line growth: knees up 21.9–22%, extremities up 38.8–39%, spine up 13.4–13.5%, hips up 8.3%.

• Revenue distribution: EMEA 48%, North America 30%, Asia-Pacific 20%, Latin America 2%.

Outlook and guidance

• Continued focus on innovation, medical education, and expanding the sales team to sustain above-market growth in 2025.

• SpheriKA and NextAR technologies anticipated to maintain strong momentum, though percentage growth may normalize as the base increases.

• More detailed 2025 guidance to be provided in March with full-year profitability results.